Viewing Study NCT03094832

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:35 PM
Ignite Modification Date: 2026-05-21 @ 1:08 PM
Study NCT ID: NCT03094832
Status: TERMINATED
Last Update Posted: 2023-04-13
First Post: 2017-03-17
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ARQ 092 View
None ArQule View
None AKT View
None PIK3CA View
None Overgrowth View
None Congenital malformations View
None Miransertib View
None MOSAIC View